Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Press Bhutan.
Press releases published on October 7, 2025
CHESS Health Launches TouchPoint to Enable Multi-Channel Patient Engagement
Rochester, New York, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CHESS Health, a leading provider of digital behavioral health solutions, today announced the launch of TouchPoint, a multi-channel engagement tool integrated within its flagship eRecovery solution. …
Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium
NORWOOD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, …
Kestra Appoints Timothy Moran as Chief Business Officer, Strengthening Leadership Team for Next Stage of Growth
KIRKLAND, Wash., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Timothy Moran as Chief Business Officer, effective November 3. …
TerrAscend to Host Third Quarter 2025 Earnings Conference Call
TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced that it will host a scheduled conference call to discuss the results for its …
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a Poster of Distinction WARMINSTER, Pa., Oct. 07, 2025 (GLOBE …
Bluejay Therapeutics Announces Data Presentations in Chronic Hepatitis D (CHD) and Chronic Hepatitis B (CHB) at Upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025
REDWOOD CITY, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver diseases, today announced upcoming …
Extendicare Announces Timing of 2025 Third Quarter Results and Conference Call
MARKHAM, Ontario, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the third quarter of 2025 after market close on Tuesday, November 11, 2025. …
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today …
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
LONDON and NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will exhibit two posters at the European Society of Gene and Cell …
CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer
BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced the appointment of Matthew Winton, Ph.D., as …
Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
HINGHAM, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) (“Microbot” or the “Company”), today announced the third and final closing of its previously announced exercise of certain outstanding preferred investment options to …
Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025
SEATTLE, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2025 before …
Biomea Fusion Announces Pricing of Public Offering of Securities
SAN CARLOS, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering consisting of (i) 11, …
Esaote enters the field of neurosurgery by presenting an innovative intraoperative MRI system
I-Genius is the result of Esaote’s research and collaboration with neurosurgeons. The results achieved using MRI systems in brain glioma surgery were presented at EANS annual Congress held in Vienna The medical and scientific neurosurgical community …
Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada
MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched MYFEMBREE® (relugolix/estradiol/norethindrone acetate) in Canada. …
Thérapeutique Knight annonce la relance de MYFEMBREE® au Canada
MONTRÉAL, 07 oct. 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc., (TSX : GUD) (« Knight »), société pharmaceutique panaméricaine (hors États-Unis) spécialisée, a annoncé aujourd’hui la relance de MYFEMBREE® (relugolix/estradiol/acétate de noréthindrone …
Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01
Dr. Kates’ experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program Phase 3 program for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., Oct. 07, 2025 ( …
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases
JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell depletion with less frequent subcutaneous dosing JADE201 …
Biomed Valley Discoveries Announces Publication of Results from Phase 1b Study of Pembrolizumab in Combination with Clostridium novyi-NT (CNV-NT/BVD-550) in Patients with Advanced Solid Tumors in Clinical Cancer Research
Led by researchers at MD Anderson Cancer Center, the study demonstrated an overall objective response rate of 25% (n=4) among patients with various solid tumor types BVD is advancing CNV-NT, an attenuated form of the Clostridium novyi bacteria delivered …
OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina
OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s previously announced strategy to add US GMP capacity across drug substance and fill-finish to meet growing client …